Back

Towards patient-relevant, trial-ready digital motor outcomes for SPG7: a cross-sectional prospective multi-center study (PROSPAX)

Beichert, L.; Seemann, J.; Kessler, C.; Traschuetz, A.; Mueller, D.; Dillmann-Jehn, K.; Ricca, I.; Satolli, S.; Basak, A. N.; Coarelli, G.; Timmann, D.; Gagnon, C.; van de Warrenburg, B.; PROSPAX consortium, ; Ilg, W.; Synofzik, M.; Schuele, R.

2024-01-10 neurology
10.1101/2024.01.09.24301064 medRxiv
Show abstract

Background and ObjectivesWith targeted treatment trials on the horizon, identification of sensitive and valid outcome measures becomes a priority for the >100 spastic ataxias. Digital-motor measures, assessed by wearable sensors, are prime outcome candidates for SPG7 and other spastic ataxias. We here aimed to identify candidate digital-motor outcomes for SPG7 - as one of the most common spastic ataxias - that: (i) reflect patient-relevant health aspects, even in mild, trial-relevant disease stages; (ii) are suitable for a multi-center setting; and (iii) assess mobility also during uninstructed walking simulating real-life. MethodsCross-sectional multi-center study (7 centers, 6 countries). Unaided walking was assessed in 65 patients with SPG7 and 50 unrelated healthy controls using 3 wearable sensors (Opal APDM). Digital gait measures were correlated to measures of disease severity (SARA, SPRS; including mobility-relevant subscores SPRS1315291292025, SARAPG) and activities of daily living (FARS-ADL). The task set included lab-based defined gait tasks, complemented by uninstructed supervised free walking. ResultsAmong 30 hypothesis-based gait measures, 18 demonstrated at least moderate effect size (Cliffs {delta}>0.5) in discriminating SPG7 patients from controls, and 17 even in mild disease stages (SPRSmobility[&le;]9). Spatiotemporal variability measures such as the spatial variability composite measure SPcmp ({rho}=0.67, p=<0.0001), Stride Time CV ({rho}=0.67, p=<0.0001) and Swing CV ({rho}=0.64, p=<0.0001) showed the highest correlations with clinician-reported mobility scores (SPRSmobility), and overall disease severity (SPRS, SARA). Overall, top-ranked measures also correlated with patient-relevant functional deficits in everyday life activities (FARS-ADL). In mild disease stages (SPRSmobility[&le;]9, n=41), Swing CV ({rho}=0.53, p=<0.0001) and SPcmp ({rho}=0.50, p=<0.0001) correlated with SPRSmobility. In the uninstructed supervised free walking task, the correlations between spatiotemporal variability measures (Stride Time CV, Stride Length CV, Swing CV) and SPRSmobility could be confirmed; additionally, Gait Speed ({rho}=-0.59, p=<0.0001) was highly correlated with SPRSmobility. DiscussionWe here identified trial-ready digital-motor candidate outcomes for the spastic ataxia SPG7, all characterized by proven multi-center applicability, ability to discriminate patients from controls, and correlation with measures of disease severity - even in mild disease stages -, and patient-relevant everyday function. If validated longitudinally, these sensor outcomes might inform future natural history and treatment trials in SPG7 and other spastic ataxias.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.